Sign in3 stories
The company said rademikibart cut treatment failure by 81% and new exacerbations by 85% versus placebo in the Seabreeze STAT COPD trial, and plans to seek FDA alignment on Phase 3.
SEC filing
The company said rademikibart cut treatment failures by 66% versus placebo, though the result missed statistical significance, while lung function improved significantly at Day 7.
SEC filing
The company expects topline data from both Seabreeze STAT trials of rademikibart in September 2026 and plans to meet the FDA afterward on a Phase 3 program.
SEC filing